The Food and Drug Administration will allow Dynavax Technologies Corp. (Nasdaq: DVAX) to continue drug trials of its hepatitis B vaccine sending the stock price soaring 91 cents to $2.66.
Dynavax Resumes Hepatitis B Vaccine Trials
September 10, 2009 at 13:14 PM EDT
